Implications of “no deal” Brexit for orphan and paediatric medicines

Research output: Other contribution

Abstract

In the event of a “no deal” Brexit some of the UK’s most vulnerable, especially children with rare diseases, may lose access to the best medicine available, say Stuart Elborn, Mark Flear, and Damian Downey.
Original languageEnglish
TypeBlog entry
Media of outputBMJ Opinion blog
Publication statusPublished - 19 Jul 2019

Publication series

NameBMJ Blogs

Fingerprint

Rare Diseases
Medicine
Pediatrics

Cite this

@misc{74b086a3a6f849e3bbbb7015c25c61fe,
title = "Implications of “no deal” Brexit for orphan and paediatric medicines",
abstract = "In the event of a “no deal” Brexit some of the UK’s most vulnerable, especially children with rare diseases, may lose access to the best medicine available, say Stuart Elborn, Mark Flear, and Damian Downey.",
author = "Joseph Elborn and Mark Flear and Damian Downey",
year = "2019",
month = "7",
day = "19",
language = "English",
series = "BMJ Blogs",
type = "Other",

}

TY - GEN

T1 - Implications of “no deal” Brexit for orphan and paediatric medicines

AU - Elborn, Joseph

AU - Flear, Mark

AU - Downey, Damian

PY - 2019/7/19

Y1 - 2019/7/19

N2 - In the event of a “no deal” Brexit some of the UK’s most vulnerable, especially children with rare diseases, may lose access to the best medicine available, say Stuart Elborn, Mark Flear, and Damian Downey.

AB - In the event of a “no deal” Brexit some of the UK’s most vulnerable, especially children with rare diseases, may lose access to the best medicine available, say Stuart Elborn, Mark Flear, and Damian Downey.

M3 - Other contribution

T3 - BMJ Blogs

ER -